TikkunLev Therapeutics is pioneering the development of precision therapies to reverse heart failure by targeting the causal disease biology of failing heart muscle. With a lead program in IND-enabling development for non-ischemic DCM and a broad indication expansion pipeline focused on common, devastating forms of heart failure, TikkunLev is committed to transforming the treatment landscape for heart failure patients worldwide.